

(80155)

Medical Benefit		Effective Date: 10/01/18	Next Review Date: 07/23
Preauthorization	No	Review Dates: 07/11, 07/12, 07/13, 07/14, 07/15, 07/16, 07/17, 07/18, 07/19, 07/20, 07/21, 07/22	

This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

RELATED PROTOCOLS

Autologous Platelet-Derived Growth Factors as a Treatment of Wound Healing and Other Conditions

Orthopedic Applications of Stem Cell Therapy (Including Allograft and Bone Substitute Products Used With Autologous Bone Marrow)

Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> • With peripheral arterial disease 	Interventions of interest are: <ul style="list-style-type: none"> • Stem cell therapy 	Comparators of interest are: <ul style="list-style-type: none"> • Conservative management • Surgical intervention 	Relevant outcomes include: <ul style="list-style-type: none"> • Overall survival • Symptoms • Change in disease status • Morbid events • Functional outcomes • Quality of life • Treatment-related morbidity

DESCRIPTION

Peripheral arterial disease is a common atherosclerotic syndrome associated with significant morbidity and mortality. Critical limb ischemia (CLI) is the end stage of lower-extremity PAD in which severe obstruction of blood flow results in ischemic pain at rest, ulcers, and a significant risk for limb loss. Use of autologous stem cells freshly harvested and allogeneic stem cells are reported to have a role in the treatment of PAD.

SUMMARY OF EVIDENCE

For individuals who have peripheral arterial disease (PAD) who receive stem cell therapy, the evidence includes small randomized trials and systematic reviews. Relevant outcomes are overall survival, symptoms, change in

disease status, morbid events, functional outcomes, quality of life, and treatment-related morbidity. The current literature on stem cells as a treatment for CLI due to PAD consists primarily of phase 2 studies using various cell preparation methods and methods of administration. A meta-analysis of the trials with the lowest risk of bias has shown no significant benefit of stem cell therapy for overall survival, amputation-free survival, or amputation rates. Three randomized controlled trials (RCTs) have been published that used granulocyte colony-stimulating factor (GM-CSF)-mobilized peripheral blood mononuclear cells (PBMNC). The route of administration of cell therapy and the primary outcomes differed between studies. In the trial that added cell therapy to guideline-based care, there were no significant differences in progression-free survival and frequency of limb amputation at 1 year of follow-up. There was a substantial rate of subsequent surgical intervention in both arms. Well-designed RCTs with a larger number of subjects and low-risk of bias are needed to evaluate the health outcomes of these various procedures. Several are in progress, including multicenter randomized, double-blind, placebo-controlled trials. More data on the safety and durability of these treatments are also needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

POLICY

Treatment of peripheral arterial disease, including critical limb ischemia, with injection or infusion of stem cells from concentrated bone marrow, expanded in vitro, stimulated from peripheral blood, or from an allogeneic source, is considered **investigational**.

BACKGROUND

PERIPHERAL ARTERIAL DISEASE

Peripheral arterial disease (PAD) is a common atherosclerotic syndrome associated with significant morbidity and mortality. A less common cause of PAD is Buerger disease (also called thromboangiitis obliterans), which is a nonatherosclerotic segmental inflammatory disease that occurs in younger patients and is associated with tobacco use. The development of PAD is characterized by narrowing and occlusion of arterial vessels and eventual reduction in distal perfusion. Critical limb ischemia is the end stage of lower-extremity PAD in which severe obstruction of blood flow results in ischemic pain at rest, ulcers, and a significant risk for limb loss.

Physiology

Two endogenous compensating mechanisms may occur with occlusion of arterial vessels: capillary growth (angiogenesis) and development of collateral arterial vessels (arteriogenesis). Capillary growth is mediated by the hypoxia-induced release of chemokines and cytokines such as vascular endothelial growth factor and occurs by sprouting of small endothelial tubes from preexisting capillary beds. The resulting capillaries are small and cannot sufficiently compensate for a large occluded artery. Arteriogenesis with collateral growth is, in contrast, initiated by increasing shear forces against vessel walls when blood flow is redirected from the occluded transport artery to the small collateral branches, leading to an increase in the diameter of preexisting collateral arterioles.

The mechanism underlying arteriogenesis includes the migration of bone marrow-derived monocytes to the perivascular space. The bone marrow-derived monocytes adhere to and invade the collateral vessel wall. It is not known if the expansion of the collateral arteriole is due to the incorporation of stem cells into the wall of the vessel or to cytokines released by monocytic bone marrow cells that induce the proliferation of resident endothelial cells. It has been proposed that bone marrow-derived monocytic cells may be the putative circulating endothelial progenitor cells. Notably, the same risk factors for advanced ischemia (diabetes, smoking, hyperlipidemia, advanced age) are also risk factors for a lower number of circulating progenitor cells.

Treatment

Use of autologous stem cells freshly harvested and allogeneic stem cells are reported to have a role in the treatment of PAD. Stem cells can be administered in a variety of routes, derived from different progenitors, and be grouped with different co-factors, many of which are being studied in order to determine the best clinical option for patients. The primary outcome in stem cell therapy trials regulated by the U.S. Food and Drug Administration (FDA) is amputation-free survival, defined as time to major amputation and/or death from any cause. Other outcomes for critical limb ischemia include the Rutherford criteria for limb status, healing of ulcers, the Ankle-Brachial Index (ABI), transcutaneous oxygen pressure, and pain-free walking. The ABI measures arterial segmental pressures on the ankle and brachium and indexes ankle systolic pressure against brachial systolic pressure (normative range, 0.95 to 1.2 mm Hg).

REGULATORY STATUS

Six point-of-care concentrations of bone marrow aspirate have been cleared by the FDA through the 510(k) process and are summarized in Table 1.

Table 1. FDA Approved Point-of-Care Concentration of Bone Marrow Aspirate Devices

Device	Manufacturer	Location	Date Cleared	510(k) No.
The SmarktPReP2® Bone Marrow Aspirate Concentrate System, SmarktPReP Platelet Concentration System	Harvest Technologies	Lakewood, CO	12/06/2010	K103340
MarrowStim Concentration System (MSC system)	Biomet Biologics, Inc	Warsaw, IN	12/18/2009	BK090008
PureBMC SupraPhysiologic Concentrating System	EmCyte Corporation®	Fort Myers, Florida	5/30/2019	K183205
Arthrex Angel System Kit	Arthrex, Inc.	Naples, Florida	5/23/2018	BK180180
Magellan® Autologous Platelet Separator System	Arteriocyte Medical Systems (Medtronic)	Memphis, TN	11/09/2004	BK040068
BioCUE Platelet Concentration Kit	Biomet Biologics, Inc.	Warsaw, IN	5/26/2010	BK1000027
ART BMC System	SpineSmith Holdings, LLC	Austin, TX	Not available	Not available
PXP® System	ThermoGenesis Corp.	Rancho Cordova, CA	07/10/2002	K081345

Food and Drug Administration product code: JQC.

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. *J Vasc Surg*. Feb 2011;53(2):445-53. PMID 21030198
2. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. *Atherosclerosis*. Mar 2010;209(1):10-7. PMID 19740466
3. Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. *Circ Res*. Apr 14 2017; 120(8):1326-1340. PMID 28096194
4. Xie B, Luo H, Zhang Y, et al. Autologous Stem Cell Therapy in Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials. *Stem Cells Int*. 2018;2018:7528464. PMID 29977308
5. Gao W, Chen D, Liu G, et al. Autologous stem cell therapy for peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. *Stem Cell Res Ther*. May 21 2019;10(1):140. PMID 31113463
6. Prochazka V, Gumulec J, Jaluvka F, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. *Cell Transplant*. 2010;19(11):1413-24. PMID 20529449
7. Benoit E, O'Donnell TF, lafrati MD, et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. *J Transl Med*. Sep 27 2011;9:165. PMID 21951607
8. Skora J, Pupka A, Janczak D, et al. Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia. *Arch Med Sci*. Apr 25 2015;11(2):325-31. PMID 25995748
9. Gupta PK, Krishna M, Chullikana A, et al. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy. *Stem Cells Transl Med*. Mar 2017;6(3):689-699. PMID 28297569
10. Teraa M, Sprengers RW, Schutgens RE, et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. *Circulation*. Mar 10 2015;131(10):851-60. PMID 25567765
11. Peeters Weem SM, Teraa M, den Ruijter HM, et al. Quality of Life After Treatment with Autologous Bone Marrow Derived Cells in No Option Severe Limb Ischemia. *Eur J Vasc Endovasc Surg*. Jan 2016;51(1):83-9. PMID 26511056
12. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). *Circ Cardiovasc Interv*. Feb 01 2011;4(1):26-37. PMID 21205939
13. Powell RJ, Comerota AJ, Berceci SA, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. *J Vasc Surg*. Oct 2011;54(4):1032-41. PMID 21684715
14. Powell RJ, Marston WA, Berceci SA, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. *Mol Ther*. Jun 2012;20(6):1280-6. PMID 22453769
15. Poole J, Mavromatis K, Binongo JN, et al. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial. *JAMA*. Dec 25 2013;310(24):2631-9. PMID 24247554
16. McDermott MM, Ferrucci L, Tian L, et al. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. *JAMA*. Dec 05 2017;318(21):2089-2098. PMID 29141087
17. Horie T, Yamazaki S, Hanada S, et al. Outcome From a Randomized Controlled Clinical Trial - Improvement of Peripheral Arterial Disease by Granulocyte Colony-Stimulating Factor-Mobilized Autologous Peripheral-Blood-Mononuclear Cell Transplantation (IMPACT). *Circ J*. Jul 25 2018;82(8):2165-2174. PMID 29877199

18. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. Mar 21 2017;69(11):e71-e126. PMID 27851992
19. Valentine EA, Ochroch EA. 2016 American College of Cardiology/American Heart Association Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Perioperative Implications. *J Cardiothorac Vasc Anesth*. Oct 2017;31(5):1543-1553. PMID 28826846
20. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *J Vasc Surg*. Jun 2019;69(6S):3S-125S.e40. PMID 31159978
21. Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. Nov 2011;32(22):2851-906. PMID 21873417
22. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*. Mar 01 2018;39(9):763-816. PMID 28886620